{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : true,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006954",
      "entity_text" : "inflammation",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04171",
      "entity_text" : "imrecoxib 0.4",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In short, a three-month, randomized, double-blind, positive drug controlled observational study showed that imrecoxib 0.4 g/d was not inferior to celecoxib 0.4 g/d in the control of symptoms of axSpA, reducing inflammation and disease activities, improving mobility function, and other disease aspects.",
  "reading_complete" : "2020-08-04T17:36:03Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T17:35:09Z",
  "trigger" : "reducing",
  "evidence" : [ "imrecoxib 0.4 g/d was not inferior to celecoxib 0.4 g/d in the control of symptoms of axSpA, reducing inflammation" ],
  "pmc_id" : "5486680",
  "score" : 0
}